ZyVersa Historical Income Statement
| ZVSA Stock | 1.13 0.01 0.88% |
Historical analysis of ZyVersa Therapeutics income statement accounts such as Depreciation And Amortization of 8.3 K, Interest Expense of 444.5 K, Selling General Administrative of 11.8 B or Total Revenue of 0.0 can show how well ZyVersa Therapeutics performed in making a profits. Evaluating ZyVersa Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ZyVersa Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ZyVersa Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ZyVersa Therapeutics is a good buy for the upcoming year.
ZyVersa |
About ZyVersa Income Statement Analysis
ZyVersa Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ZyVersa Therapeutics shareholders. The income statement also shows ZyVersa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ZyVersa Therapeutics Income Statement Chart
Add Fundamental
Cost Of Revenue
Cost of Revenue is found on ZyVersa Therapeutics income statement and represents the costs associated with goods and services ZyVersa Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on ZyVersa Therapeutics income statement and is an important metric when analyzing ZyVersa Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from ZyVersa Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ZyVersa Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.At present, ZyVersa Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 3.4 M, whereas Net Interest Income is forecasted to decline to (51.6 K).
| 2023 | 2024 (projected) | Interest Expense | 457K | 444.5K | Depreciation And Amortization | 9.4K | 8.3K |
ZyVersa Therapeutics income statement Correlations
Click cells to compare fundamentals
ZyVersa Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.